Transplantation for Myeloma - Now or Later?

Overview

Journal N Engl J Med

Specialty General Medicine

Date 2017 Apr 6

PMID 28379801

Citations 3

Authors

Charles A Schiffer

Jeffrey A Zonder

Affiliations

Soon will be listed here.

Citing Articles

Chimeric Antigen Receptor T Cell Therapy versus Hematopoietic Stem Cell Transplantation: An Evolving Perspective.

Goldsmith S, Ghobadi A, Dipersio J, Hill B, Shadman M, Jain T Transplant Cell Ther. 2022; 28(11):727-736.

PMID: 35878743 PMC: 10487280. DOI: 10.1016/j.jtct.2022.07.015.

Novel Agents in Multiple Myeloma.

Szalat R, Munshi N Cancer J. 2019; 25(1):45-53.

PMID: 30694859 PMC: 6589825. DOI: 10.1097/PPO.0000000000000355.

Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time.

Kumar S, Dispenzieri A, Fraser R, Mingwei F, Akpek G, Cornell R Leukemia. 2017; 32(4):986-995.

PMID: 29263438 PMC: 5871538. DOI: 10.1038/leu.2017.331.

References

Attal M, Harousseau J, Stoppa A, Sotto J, Fuzibet J, Rossi J . A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996; 335(2):91-7. DOI: 10.1056/NEJM199607113350204. View

Fermand J, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C . High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood. 1998; 92(9):3131-6. View

Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F . Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the.... Blood. 2002; 99(3):731-5. DOI: 10.1182/blood.v99.3.731. View

Attal M, Harousseau J, Facon T, Guilhot F, Doyen C, Fuzibet J . Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003; 349(26):2495-502. DOI: 10.1056/NEJMoa032290. View

Jagannath S, Vesole D, Glenn L, Crowley J, Barlogie B . Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood. 1992; 80(7):1666-72. View

Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M . Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med. 2017; 376(14):1311-1320. PMC: 6201242. DOI: 10.1056/NEJMoa1611750. View

Kumar S, Dispenzieri A, Lacy M, Gertz M, Buadi F, Pandey S . Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2013; 28(5):1122-8. PMC: 4000285. DOI: 10.1038/leu.2013.313. View

Durie B, Hoering A, Abidi M, Rajkumar S, Epstein J, Kahanic S . Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2016; 389(10068):519-527. PMC: 5546834. DOI: 10.1016/S0140-6736(16)31594-X. View

Barlogie B, Hall R, Zander A, Dicke K, Alexanian R . High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood. 1986; 67(5):1298-301. View

10.

Child J, Morgan G, Davies F, Owen R, Bell S, Hawkins K . High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003; 348(19):1875-83. DOI: 10.1056/NEJMoa022340. View